Harrow Health Inc. 8.625%... (HROWL)
25.02
0.01 (0.04%)
At close: Apr 21, 2025, 3:57 PM
25.03
0.04%
After-hours: Apr 21, 2025, 04:00 PM EDT
Company Description
Harrow, Inc. engages in the development, production, and sale of innovative medications.
It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.
The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business.
The company was founded by Mark L.
Baum and Robert J.
Kammer in January 2006 and is headquartered in Nashville, TN.
Harrow Health Inc. 8.625% Senior Notes due 2026
| Country | United States |
| IPO Date | May 7, 2021 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 217 |
| CEO | Mark L. Baum |
Contact Details
Address: No Address available Nashville, Delaware United States | |
| Website | http://www.harrowinc.com |
Stock Details
| Ticker Symbol | HROWL |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001360214 |
| CUSIP Number | n/a |
| ISIN Number | US4158582084 |
| Employer ID | 45-0567010 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 07, 2025 | 4 | Filing |
| Apr 07, 2025 | 4 | Filing |
| Apr 07, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Apr 07, 2025 | 4 | Filing |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 4 | Filing |
| Mar 20, 2025 | 4 | Filing |
| Mar 17, 2025 | NT 10-K | Filing |
| Mar 17, 2025 | 8-K | Current Report |